Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer.
Ryan ST, Zhang J, Burner DN, Liss M, Pittman E, Muldong M, Shabaik A, Woo J, Basler N, Cunha J, Shalapour S, Estrada MV, Karin M, Messer K, Howell S, Kane CJ, Jamieson CAM.
Ryan ST, et al. Among authors: howell s.
J Transl Med. 2020 May 28;18(1):214. doi: 10.1186/s12967-020-02370-4.
J Transl Med. 2020.
PMID: 32466781
Free PMC article.
Clinical Trial.